Effectiveness of infection-containment measures on SARS-CoV-2 seroprevalence and circulation from May to July 2020, in Milan, Italy.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2020
Historique:
received: 10 08 2020
accepted: 09 11 2020
entrez: 20 11 2020
pubmed: 21 11 2020
medline: 2 12 2020
Statut: epublish

Résumé

Through a hospital-based SARS-CoV-2 molecular and serological screening, we evaluated the effectiveness of two months of lockdown and two of surveillance, in Milan, Lombardy, the first to be overwhelmed by COVID-19 pandemics during March-April 2020. All subjects presenting at the major hospital of Milan from May-11 to July-5, 2020, underwent a serological screening by chemiluminescent assays. Those admitted were further tested by RT-PCR. The cumulative anti-N IgG seroprevalence in the 2753 subjects analyzed was of 5.1% (95%CI = 4.3%-6.0%), with a peak of 8.4% (6.1%-11.4%) 60-63 days since the peak of diagnoses (March-20). 31/106 (29.2%) anti-N reactive subjects had anti-S1/S2 titers >80 AU/mL. Being tested from May-18 to June-5, or residing in the provinces with higher SARS-CoV-2 circulation, were positively and independently associated with anti-N IgG reactivity (OR [95%CI]: 2.179[1.455-3.264] and 3.127[1.18-8.29], respectively). In the 18 RT-PCR positive, symptomatic subjects, anti-N seroprevalence was 33.3% (95% CI: 14.8%-56.3%). SARS-CoV-2 seroprevalence in Milan is low, and in a downward trend after only 60-63 days since the peak of diagnoses. Italian confinement measures were effective, but the risk of contagion remains concrete. In hospital-settings, the performance of molecular and serological screenings upon admission remains highly advisable.

Identifiants

pubmed: 33216817
doi: 10.1371/journal.pone.0242765
pii: PONE-D-20-24967
pmc: PMC7679019
doi:

Substances chimiques

Antibodies, Viral 0
Immunoglobulin G 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0242765

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Clin Microbiol Infect. 2020 Jun 25;:
pubmed: 32593741
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32381641
Virus Res. 2014 Dec 19;194:175-83
pubmed: 24670324
Euro Surveill. 2020 Jun;25(24):
pubmed: 32583766
Clin Diagn Lab Immunol. 2004 Mar;11(2):362-71
pubmed: 15013989
Clin Microbiol Infect. 2020 Jun 9;:
pubmed: 32531475
J Med Virol. 2020 Jun 2;:
pubmed: 32484942
Clin Infect Dis. 2020 Jun 16;:
pubmed: 32556191
Clin Chem. 2020 Aug 1;66(8):1055-1062
pubmed: 32402061
N Engl J Med. 2020 Jun 11;382(24):2302-2315
pubmed: 32289214
Cochrane Database Syst Rev. 2020 Jun 25;6:CD013652
pubmed: 32584464
J Clin Microbiol. 2005 Jul;43(7):3054-8
pubmed: 16000415
Lancet. 2020 Aug 1;396(10247):313-319
pubmed: 32534626
JAMA. 2020 May 19;323(19):1881-1883
pubmed: 32301958
Lancet. 2020 Aug 22;396(10250):535-544
pubmed: 32645347
Nature. 2020 Aug;584(7821):425-429
pubmed: 32604404

Auteurs

Valeria Cento (V)

Chemical-Clinical and Microbiological Analyses, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy.

Claudia Alteri (C)

Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy.

Marco Merli (M)

Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.

Federica Di Ruscio (F)

Chemical-Clinical and Microbiological Analyses, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
Residency in Microbiology and Virology, Università degli Studi di Milano, Milan, Italy.

Livia Tartaglione (L)

Chemical-Clinical and Microbiological Analyses, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
Residency in Microbiology and Virology, Università degli Studi di Milano, Milan, Italy.

Roberto Rossotti (R)

Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.

Giovanna Travi (G)

Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.

Marta Vecchi (M)

Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.

Alessandro Raimondi (A)

Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.

Alice Nava (A)

Chemical-Clinical and Microbiological Analyses, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.

Luna Colagrossi (L)

Residency in Microbiology and Virology, Università degli Studi di Milano, Milan, Italy.

Roberto Fumagalli (R)

Department of Anesthesiology, Critical Care and Pain Medicine, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.

Nicola Ughi (N)

Rheumatology Unit, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.

Oscar Massimiliano Epis (OM)

Rheumatology Unit, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.

Diana Fanti (D)

Chemical-Clinical and Microbiological Analyses, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.

Andrea Beretta (A)

Emergency Medicine, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.

Filippo Galbiati (F)

Emergency Medicine, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.

Francesco Scaglione (F)

Chemical-Clinical and Microbiological Analyses, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy.

Chiara Vismara (C)

Chemical-Clinical and Microbiological Analyses, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.

Massimo Puoti (M)

Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.

Daniela Campisi (D)

Chemical-Clinical and Microbiological Analyses, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.

Carlo Federico Perno (CF)

Chemical-Clinical and Microbiological Analyses, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH